Navigation Links
Avicena Appoints Dr. M. Flint Beal to Board of Directors
Date:9/28/2007

PALO ALTO, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today the appointment of Dr. M. Flint Beal, M.D. to the Company's Board of Directors, effective October 30, 2007. Dr. Beal is a co-founder of Avicena and has served as a member of the Company's Scientific Advisory Board since 2000. This appointment expands the Board of Directors to 6 members.

"Dr. Beal, an internationally recognized authority on neurodegenerative disorders, is a welcome addition to our Board of Directors. As a co-founder of Avicena and a current member of our Scientific Advisory Board, he is particularly well suited to help guide us through our drug development programs," stated Belinda Tsao-Nivaggioli, Avicena's chief executive officer. "Avicena is entering into an important stage with Phase III studies in Parkinson's Disease, Huntington's Disease and ALS and we are looking forward to Dr. Beal's contributions."

Dr. Beal is the Anne Parrish Titzell professor and chairman of the department of neurology and neuroscience at the Weill Medical College at Cornell University, and director of neurology at New York Presbyterian Hospital. Prior to Cornell, Dr. Beal was the professor of neurology at the Harvard Medical School and chief of the neurochemistry laboratory at Massachusetts General Hospital.

Dr. Beal is also involved with several foundations and associations focused on neurological disorders, including the Alpha Omega Alpha Medical Honorary Society, where he received the Derek Denny-Brown Neurological Scholar Award of the American Neurologic Association. He is also a member of the Institute of Medicine of the National Academy of Science, and was previously on the Council of the American Neurologic Association. In addition, Dr. Beal served on the science advisory committees of the Hereditary Disease F
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of JRC-LAMP-vax, ... Japanese red cedar pollen. Phase IC studies began this ... real solution to hay fever. , The Japanese red ... 35 million people in Japan. Mountain Cedar pollen wreaks ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... (Amex:,SGN) has announced that the legendary Earvin "Magic" ... ambulatory heart testing with AFL,s,flagship choice, Signalife,s Fidelity ... the greatest basketball superstars of all time, Mr.,Johnson ... multiple,championships from college to the Los Angeles Lakers ...
... September 13, 2007 at the 14th, International Symposium on Hepatitis C ... ... Glasgow, Scotland, VALLEY COTTAGE, New York, September 6 XTL,Biopharmaceuticals ... a late breaker abstract, entitled "Potent Small Molecule HCV,Inhibitors Affecting NS5A-dependent ...
... They,ve gotten the science wrong. They,ve gotten the law wrong. Why ... we trust them ... Coalition for,Lifesaving Cures responded today as opponents of stem cell cures ... weeks. Said Donn Rubin, Chair of Missouri Coalition for Lifesaving ...
Cached Biology Technology:Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team 2Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team 3XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference 23 strikes, you're out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause 2
(Date:8/22/2014)... to important discoveries in basic and clinical research ... mobilized into a complex offensive spanning multiple fronts. ... chemistry lab could help find new and more ... compound that targets a specific enzyme overexpressed in ... cells from brain tumours. , Chemistry professor Christopher ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. ... growing mobile commerce market, announced today that its shares ... stock to be issued in its proposed underwritten public ... for listing on The Nasdaq Capital Market, subject to ... common stock and warrants, and will trade under the ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... a paradox that,s puzzled scientists for a half-century. ... depends on those species responding differently to the availability ... species draw a blank? Competitors like black gums ... shaded understories of eastern U.S. forests, yet species-level data ...
... for the study of stem cells and to increase capacity ... initiatives announced today by NIH Director Francis S. Collins, M.D., ... Common Fund, which encourages collaborative research programs across the NIH ... single IC could do alone. The programs are all scheduled ...
... , ... ... ... , ...
Cached Biology News:Forest tree species diversity depends on individual variation 2Forest tree species diversity depends on individual variation 3Emerging science, tech advances highlight new NIH Common Fund programs 2Emerging science, tech advances highlight new NIH Common Fund programs 3Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 2Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 3Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 4Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 5Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 6
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Request Info...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: